SG10202002010VA - Compositions that metabolize or sequester free sugar monomers and uses thereof - Google Patents

Compositions that metabolize or sequester free sugar monomers and uses thereof

Info

Publication number
SG10202002010VA
SG10202002010VA SG10202002010VA SG10202002010VA SG10202002010VA SG 10202002010V A SG10202002010V A SG 10202002010VA SG 10202002010V A SG10202002010V A SG 10202002010VA SG 10202002010V A SG10202002010V A SG 10202002010VA SG 10202002010V A SG10202002010V A SG 10202002010VA
Authority
SG
Singapore
Prior art keywords
metabolize
compositions
free sugar
sugar monomers
sequester free
Prior art date
Application number
SG10202002010VA
Inventor
David Kyle
David Mills
Carlito Lebrilla
Samara Freeman-Sharkey
Steven Frese
Original Assignee
Evolve Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evolve Biosystems Inc filed Critical Evolve Biosystems Inc
Publication of SG10202002010VA publication Critical patent/SG10202002010VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
SG10202002010VA 2015-03-13 2016-03-11 Compositions that metabolize or sequester free sugar monomers and uses thereof SG10202002010VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562133239P 2015-03-13 2015-03-13

Publications (1)

Publication Number Publication Date
SG10202002010VA true SG10202002010VA (en) 2020-05-28

Family

ID=56919333

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10202002010VA SG10202002010VA (en) 2015-03-13 2016-03-11 Compositions that metabolize or sequester free sugar monomers and uses thereof
SG11201707506WA SG11201707506WA (en) 2015-03-13 2016-03-11 Compositions that metabolize or sequester free sugar monomers and uses thereof
SG10202101108RA SG10202101108RA (en) 2015-03-13 2016-03-11 Compositions that metabolize or sequester free sugar monomers and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG11201707506WA SG11201707506WA (en) 2015-03-13 2016-03-11 Compositions that metabolize or sequester free sugar monomers and uses thereof
SG10202101108RA SG10202101108RA (en) 2015-03-13 2016-03-11 Compositions that metabolize or sequester free sugar monomers and uses thereof

Country Status (9)

Country Link
US (2) US20180078589A1 (en)
EP (1) EP3268019A4 (en)
CN (2) CN116270760A (en)
AU (2) AU2016233529B2 (en)
BR (1) BR112017019468A2 (en)
CA (1) CA2979529A1 (en)
MX (1) MX2017011669A (en)
SG (3) SG10202002010VA (en)
WO (1) WO2016149149A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG191394A1 (en) 2010-12-31 2013-08-30 Abbott Lab Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
US9539269B2 (en) 2010-12-31 2017-01-10 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
ES2657744T3 (en) 2011-07-22 2018-03-06 Abbott Laboratories Galactoligosaccharides to prevent injuries and / or promote healing of the gastrointestinal tract
EP2750523A1 (en) 2011-08-29 2014-07-09 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
JP6868562B2 (en) 2014-10-31 2021-05-19 ペンデュラム セラピューティクス， インコーポレイテッド Methods and compositions for microbial treatment and diagnosis of disorders
ES2755815T3 (en) 2016-09-13 2020-04-23 Allergan Inc Stabilized non-protein Clostridium toxin compositions
CN106498087B (en) * 2016-12-30 2020-01-07 广东环凯生物科技有限公司 Clostridium perfringens dry pulverization LAMP (loop-mediated isothermal amplification) rapid detection kit and use method thereof
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. Methods and compositions for treatment of microbiome-associated disorders
CN110327079A (en) * 2019-06-28 2019-10-15 广州国盛基因信息科技有限公司 A kind of intestinal flora detection system
WO2023118510A1 (en) 2021-12-22 2023-06-29 N.V. Nutricia Mix of specific bifidobacterium species and specific non-digestible oligosaccharides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716615A (en) * 1992-02-10 1998-02-10 Renata Maria Anna Cavaliere Vesely Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use
RU2180915C1 (en) * 2001-04-28 2002-03-27 Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского Consortium of bifidobacteria and lactobacilli used for preparing bacterial preparations, ferments for fermented-milk foodstuffs, fermented and nonfermented foodstuffs, biologically active supplements designated for correction of microflora in children in age below 3 years
EP1776877A1 (en) * 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
WO2007140622A1 (en) * 2006-06-09 2007-12-13 Nutravital Inc. Dairy-derived probiotic compositions and uses thereof
US20100166721A1 (en) * 2006-06-09 2010-07-01 Fabiola Masri Probotic compositions and uses thereof
JP5074146B2 (en) * 2007-03-30 2012-11-14 オリンパス株式会社 Capsule medical device
UA32462U (en) * 2008-02-14 2008-05-12 Харьковский Национальный Медицинский Университет Method for evaluation of effectiveness of correction of distortions of intestines microbiotsenosis in children of early age with atopic dermatitis
US9649380B2 (en) * 2009-01-12 2017-05-16 Pfizer Italia S.R.L. Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin
US9579353B2 (en) * 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
CN107249611A (en) * 2014-10-24 2017-10-13 进化生物***股份有限公司 The Bifidobacterium of activation and its application process
US10350249B2 (en) * 2014-12-12 2019-07-16 The Regents Of The University Of California Reduction of milk glycans and their degradation products in the neonate gut

Also Published As

Publication number Publication date
BR112017019468A2 (en) 2018-05-15
WO2016149149A1 (en) 2016-09-22
SG10202101108RA (en) 2021-03-30
SG11201707506WA (en) 2017-10-30
US20180078589A1 (en) 2018-03-22
EP3268019A4 (en) 2018-10-31
CN107847533A (en) 2018-03-27
CA2979529A1 (en) 2016-09-22
CN116270760A (en) 2023-06-23
MX2017011669A (en) 2017-11-06
AU2022201172A1 (en) 2022-03-17
US20200237836A1 (en) 2020-07-30
AU2016233529B2 (en) 2022-03-10
EP3268019A1 (en) 2018-01-17
AU2016233529A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
HK1258900A1 (en) Delivery methods and compositions
HK1256225A1 (en) Oligonucleotide compositions and methods thereof
HK1255370A1 (en) Oligonucleotide compositions and methods thereof
HK1249028A1 (en) Self-foaming compositions and methods
SG11201707506WA (en) Compositions that metabolize or sequester free sugar monomers and uses thereof
GB2546350B (en) Compositions and methods
EP3325620A4 (en) Antiviral methods and compositions
IL259867B (en) Polyelectrolyte-layer forming block copolymers and compositions and uses thereof
ZA201803451B (en) Probiotic compositions and uses thereof
ZA201803875B (en) Interleukin-15 compositions and uses thereof
SG11201707876YA (en) Microalgal compositions and uses thereof
GB201718876D0 (en) Antithrombin-heparin compositions and methods
SG11201605762QA (en) Block copolymer composition and adhesive composition
SG11201605714VA (en) Block copolymer and adhesive composition
GB201500692D0 (en) Curable compositions and membranes
IL259202A (en) Modified immune cells and uses thereof
GB201502002D0 (en) Uses and compositions
EP3316871A4 (en) Talc-bound compositions and uses thereof
IL254241A0 (en) Etv2 and uses thereof
SG10202112759SA (en) Antimalarial compositions and uses thereof
HK1250915A1 (en) Composition and uses thereof
GB201502026D0 (en) Uses and compositions
GB201501991D0 (en) Uses and compositions
PL3387139T3 (en) Beta-glucosidase and uses thereof
GB201512996D0 (en) Compositions and methods